Trials / Completed
CompletedNCT01644877
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Ansun Biopharma, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DAS181 dry powder, formulation F02 | |
| DRUG | Lactose Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-12-15
- Completion
- 2016-12-15
- First posted
- 2012-07-19
- Last updated
- 2017-09-25
Locations
45 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01644877. Inclusion in this directory is not an endorsement.